CA2024631A1 - Granules a double enrobage - Google Patents

Granules a double enrobage

Info

Publication number
CA2024631A1
CA2024631A1 CA2024631A CA2024631A CA2024631A1 CA 2024631 A1 CA2024631 A1 CA 2024631A1 CA 2024631 A CA2024631 A CA 2024631A CA 2024631 A CA2024631 A CA 2024631A CA 2024631 A1 CA2024631 A1 CA 2024631A1
Authority
CA
Canada
Prior art keywords
double
coated granules
disodium pamidronate
capsules
granules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2024631A
Other languages
English (en)
Other versions
CA2024631C (fr
Inventor
Dagmar Wirth
Christian Bucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of CA2024631A1 publication Critical patent/CA2024631A1/fr
Application granted granted Critical
Publication of CA2024631C publication Critical patent/CA2024631C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Glanulating (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
CA002024631A 1989-09-07 1990-09-05 Granules a double enrobage Expired - Lifetime CA2024631C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH324589 1989-09-07
CH3245/89-3 1989-09-07

Publications (2)

Publication Number Publication Date
CA2024631A1 true CA2024631A1 (fr) 1991-03-08
CA2024631C CA2024631C (fr) 2000-11-21

Family

ID=4251793

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002024631A Expired - Lifetime CA2024631C (fr) 1989-09-07 1990-09-05 Granules a double enrobage

Country Status (21)

Country Link
US (1) US5096717A (fr)
EP (1) EP0421921B1 (fr)
JP (1) JP3009713B2 (fr)
KR (1) KR910005852A (fr)
AT (1) ATE104856T1 (fr)
AU (1) AU623036B2 (fr)
CA (1) CA2024631C (fr)
DD (1) DD298049A5 (fr)
DE (1) DE59005517D1 (fr)
DK (1) DK0421921T3 (fr)
ES (1) ES2052228T3 (fr)
FI (1) FI93169C (fr)
HU (1) HU207447B (fr)
IE (1) IE63668B1 (fr)
IL (1) IL95558A (fr)
MX (1) MX22254A (fr)
NO (1) NO176646C (fr)
NZ (1) NZ235187A (fr)
PH (1) PH27186A (fr)
PT (1) PT95209B (fr)
ZA (1) ZA907100B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520119A1 (fr) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Composition à base de diclofenac pour l'administration orale
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
EP0596962A4 (en) * 1991-07-24 1997-01-15 Enzacor Pty Ltd Therapeutic compositions and methods.
EP0613373B1 (fr) * 1991-11-22 2000-08-02 THE PROCTER & GAMBLE PHARMACEUTICALS, INC. Compositions de risedronate a liberation lente
EP0550385A1 (fr) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Compositions pharmaceutiques orales contenant des dérivés d'acide méthane-diphosphonique et des éthers 18-couronne-6
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2687291B1 (fr) * 1992-02-17 1994-06-03 Sfbd Vivis Aliment pour sportif et son procede de fabrication.
TW237386B (fr) * 1992-04-15 1995-01-01 Ciba Geigy
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
IT1260505B (it) * 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
DE4236090C1 (de) * 1992-10-26 1994-01-05 Asta Medica Arzneimittel Pharmazeutische Zubereitung für die Fluoridionen-Versorgung
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
SG108292A1 (en) * 1997-06-11 2005-01-28 Procter & Gamble Film-coated tablet for improved upper gastrointestinal tract safety
US6306438B1 (en) 1997-07-02 2001-10-23 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US6197331B1 (en) 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6984400B2 (en) * 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
WO2001032185A1 (fr) * 1999-11-02 2001-05-10 Cipla Ltd. Composition pharmaceutique renfermant au moins un acide bisphosphonique ou un de ses sels et son procede de preparation
PL196485B1 (pl) * 2000-05-11 2008-01-31 Inst Farmaceutyczny Stała doustna kompozycja farmaceutyczna zawierająca aminową pochodną kwasu bisfosfonowego i sposób jej wytwarzania
IL157634A0 (en) * 2001-03-13 2004-03-28 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms containing glucocorticosteroid
CA2347330C (fr) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Preparation injectable liquide de pamidronate disodique
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
BRPI0414311A (pt) * 2003-09-19 2008-03-04 Penwest Pharmaceutical Co formas de dosagem de liberação controlada
MXPA06003101A (es) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
WO2006018033A1 (fr) * 2004-08-20 2006-02-23 Mepha Ag Formulations de bisphosphonates
DK1880001T3 (da) * 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
CA2607949C (fr) * 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Bifidobacteries de probiotiques felins
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8663671B2 (en) * 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CA3018328A1 (fr) 2014-10-31 2016-04-30 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings

Also Published As

Publication number Publication date
AU623036B2 (en) 1992-04-30
PH27186A (en) 1993-04-16
KR910005852A (ko) 1991-04-27
JP3009713B2 (ja) 2000-02-14
FI93169B (fi) 1994-11-30
NO903892D0 (no) 1990-09-06
DD298049A5 (de) 1992-02-06
HU207447B (en) 1993-04-28
ATE104856T1 (de) 1994-05-15
ZA907100B (en) 1991-05-29
IE63668B1 (en) 1995-05-31
IE903239A1 (en) 1991-03-13
HUT59008A (en) 1992-04-28
EP0421921B1 (fr) 1994-04-27
NO176646B (no) 1995-01-30
HU905812D0 (en) 1991-03-28
NZ235187A (en) 1992-03-26
US5096717A (en) 1992-03-17
PT95209A (pt) 1991-05-22
JPH0399016A (ja) 1991-04-24
NO176646C (no) 1995-05-10
NO903892L (no) 1991-03-08
PT95209B (pt) 1998-06-30
CA2024631C (fr) 2000-11-21
MX22254A (es) 1993-12-01
AU6228390A (en) 1991-03-14
EP0421921A1 (fr) 1991-04-10
IL95558A0 (en) 1991-06-30
FI93169C (fi) 1995-03-10
DK0421921T3 (da) 1994-05-30
ES2052228T3 (es) 1994-07-01
DE59005517D1 (de) 1994-06-01
IL95558A (en) 1995-08-31
FI904341A0 (fi) 1990-09-03

Similar Documents

Publication Publication Date Title
CA2024631A1 (fr) Granules a double enrobage
CA2041260A1 (fr) Agents de contraste ultrasonore, leur procede de preparation et leur utilisation en tant qu'agents de diagnostic et de traitement
AU6770490A (en) Solid pharmaceutical compositions containing cimetidine
MY103525A (en) Pharmaceutical composition comprising cefuroxime axetil
AU3811089A (en) Chewable, edible soft gelatin capsule
IE811911L (en) Suspension-yielding powder
AU2219988A (en) Drug capsule
AU1578688A (en) Pharmaceutical composition, for oral administration, designed to attenuate the effects of beta-lactamines
EP0357793A4 (en) Suspended-release preparation prepared by using alginic acid
AU650261B2 (en) Derivatives of glycinamide, their preparation and medicaments containing them
CA2038744A1 (fr) Composition pharmaceutique contenant un medicament legerement hydrosoluble
NO881643L (no) Fremgangsmaate for fremstilling av hoeystabile mykgelatinkapsler for terapeutiske formaal.
GB1515241A (en) Beta-lactam antibiotics
CA2033418A1 (fr) Preparation pharmaceutique liquide pour administration par voie orale
NO167386C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfider med anvendelse som immunmodulatorer.
AU563822B2 (en) Pharmaceutical composition of piroxicam and 5'-guanylic acid or n-acetyl-l-methionine
NO883986D0 (no) Fremgangsmaate for fremstilling av n-(substituert alkyliden)-1,2,3,4-tetrahydro-9-akridinaminer og anvendelse derav som medikamenter.
CA2341366A1 (fr) Compositions pharmaceutiques microfines
WO1998036732A3 (fr) Preparation combinee pour antibiotiques administrables par voie orale
NO891574D0 (no) Fremgangsmaate for fremstilling av farmasoeytisk anvendbareforbindelser.
NO162468C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 12-amino-pyridazino (4[,5[;3,4)-pyrrolo-( 2,1-a)-isokinolinderivater.
CA2077762A1 (fr) Emploi du bambuterol
GB9420748D0 (en) 1,5 benzodiazepine derivatives
NO901893D0 (no) Fremgangsmaate for fremstilling av penemforbindelser.
NO166366C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cycloalkan (1,2-c:4,3-c')dipyrazoler.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry